27 September 2024 Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector.
Shares of German pharma major Bayer were up 4.6% at 30.45 euros after it released positive early trial results for its Parkinson’s disease candidate. 27 September 2024
Shionogi said today that it has submitted a New Drug Application (NDA) in Japan for zuranolone, a treatment in development for major depressive disorder (MDD). 27 September 2024
CNS specialist Lundbeck has announced data from the TALISMAN natural history study, as well as additional data from the AMULET trial, of amlenetug, in multiple system atrophy (MSA) at the International Congress of Parkinson's Disease and Movement disorders in Philadelphia, USA. 27 September 2024
Repair Biotechnologies, a company developing therapies to reverse atherosclerotic plaque, has entered into a collaboration with Genevant Sciences, a specialist in nucleic acid delivery technology. 27 September 2024
China’s National Medical Products Administration (NMPA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD). 27 September 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
US virology and immunology company Enanta Pharmaceuticals has given further weight to its claims to have the leading portfolio of potent respiratory syncytial virus (RSV) replication inhibitors 27 September 2024
Sage Therapeutics has announced that Biogen has terminated its partnership on the SAGE-324 program, following the recent failure of the drug in a Phase II study for the treatment of essential tremor. 27 September 2024
A US Food and Drug Administration advisory committee meeting has recommended restricting the use of PD-1 inhibitors, in a move which could affect blockbuster products such as Bristol Myers Squibb's Opdivo (nivolumab) and Merck & Co's Keytruda (pembrolizumab). 27 September 2024
The US Food and Drug Administration yesterday approved pharma major Bristol Myers Squibb’s Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector. 27 September 2024
US drugmaker AbbVie has announced positive topline results from its pivotal Phase III TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease. 26 September 2024
Evaxion Biotech has entered into an option and license agreement with MSD (tradename of Merck & Co outside of the USA and Canada), for two pre-clinical vaccine candidates. 26 September 2024
Danish CNS specialist Lundbeck and US privately-held biotech Iambic Therapeutics today announced a strategic research collaboration to focus on discovery of a small molecule therapeutic for the treatment of migraine. 26 September 2024
The generics and biosimilars trade group, Medicines for Europe, has put out a strong message amid ongoing discussions on a European Union (EU) Critical Medicines Act. 26 September 2024
Pfizer (NYSE: PFE) has announced the withdrawal of Oxbryta (voxelotor), a treatment for sickle cell disease (SCD), from all global markets. 26 September 2024
Not many companies in the pharmaceutical sector can say that they have kept growing and targeting growth through the pandemic, while maintaining the same commitment to their values, patients and employees. 26 November 2021
Preventing regulatory delays from slowing down the journey of new medicines from laboratory to patients in Europe is the ambition behind a new report endorsed by trade associations, patient groups and other organizations. 26 November 2021
US RNA-targeted drug developer Ionis Pharmaceuticals announced on Wednesday that partner Pfizer has provided an update on the Phase IIb study of vupanorsen, formerly IONIS-ANGPTL3-LRx. 26 November 2021
The UK subsidiary of Italian family-owned Chiesi Farmaceutici announced yesterday that pegunigalsidase alfa (PRX-102) was awarded Innovation Passport status by the UK Medicines and Healthcare products Regulatory Agency (MHRA) on August 25, 021. 26 November 2021
Japanese drug majors Takeda Pharmaceutical and Sumitomo Dainippon Pharma announced today that Takeda will succeed the manufacturing and marketing approval and the marketing rights of Replagal (agalsidase alfa) for Fabry disease, an α-galactosidase enzyme intravenous (IV) infusion, as of February 15, 2022. 26 November 2021
Fitusiran, an investigational siRNA therapeutic targeting antithrombin for the treatment of hemophilia, has shown its efficacy in late-stage trials. 25 November 2021
Japanese mid-size drugmaker Mochida Pharmaceutical and Ayumi Pharmaceutical announced that Adalimumab BS MA (adalimumab biosimilar, code: LBAL) has now been launched in Japan as the NHI (National Health Insurance) drug price has been listed today. 25 November 2021
Privately-held Italian biopharma company Dompé Farmaceutici has announced the sale of six brands to French drugmaker Substipharm, which specializes in niche generic and mature pharmaceutical products. 25 November 2021
Japanese drugmaker Ono Pharmaceutical and its partner Bristol Myers Squibb have announced the approval for the use of Opdivo (nivolumab) in two new indications in Japan. 25 November 2021
The European Medicines Agency’s human medicines committee (CHMP) has recommended granting an extension of indication for the COVID-19 vaccine Comirnaty to include use in children aged five to 11. 25 November 2021
Swiss anti-counterfeit medicine group Fight the Fakes Alliance (FTF Alliance) is gearing up for a week of action to help raise awareness around the issue of fake medicines. 25 November 2021
British specialty medicines firm Essential Pharma today announced the closing of two transactions with fellow UK-based Rosemont Pharmaceuticals. 25 November 2021
US pharma major Eli Lilly says that, following a decision by the UK’s National Institute for Health and Care Excellence (NICE), adults with advanced RET fusion-positive non-small cell lung cancer (NSCLC) will now have access to Retsevmo (selpercatinib), a targeted treatment option, via the Cancer Drugs Fund (CDF) in England. 25 November 2021
Members of the European Parliament (MEPs) yesterday put forward proposals to make medicines more affordable and boost transparency on prices and promote joint European Union public procurement. 25 November 2021
The leading Australian trade group for the pharmaceutical industry has welcomed the delivery of a report into the medicines approval process in the country. 25 November 2021
Livtencity (maribavir), an antiviral from Japanese drugmaker Takeda, has won an approval from the US Food and Drug Administration (FDA). 24 November 2021
A life-changing drug that can improve mobility in children and adults with a rare genetic condition will be available on the National Health Service (NHS) following a new commercial deal, chief executive Amanda Pritchard announced. 24 November 2021
Shares of US biotech firm Kura Oncology slumped nearly 23% to $16.60 premarket today, after it announced that the US Food and Drug Administration has placed the KOMET-001 Phase Ib study of KO-539 in patients with relapsed or refractory acute myeloid leukemia (AML) on a partial clinical hold. 24 November 2021
mTOR pathway specialist Aadi Bioscience has secured US approval for its intravenously-administered oncology therapy Fyarro (sirolimus). 24 November 2021